Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YUQ-A1007 in healthy volunteers
NCT06835296Phase 1Completed
- Sponsor
- AllianThera Biopharma
- Start
- Mar 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of YUQ-A1007 in inflammatory bowel disease (IBD) (2 arms), sponsored by AllianThera Biopharma. Primary endpoint: Safety and Tolerability of YUQ-A1007 at 6 months. Started Mar 2025; status: completed.
02
Drugs
YUQ-A1007
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT06835296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06835296.